On March 4, the US Food and Drug Administration (FDA) approved TEVIMBRA® (tislelizumab-jsgr) in combination with platinum-containing chemotherapy for the first-line treatment of adults with
unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.
To learn more, read the Beigene press release.
Posted on 3/12/25